Burke Steven Keith 4

4 · Akebia Therapeutics, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 3, 2026

Akebia (AKBA) SVP/CMO Steven Burke Receives Equity Award

What Happened

Steven Keith Burke, SVP and Chief Medical Officer of Akebia Therapeutics (AKBA), was granted two equity awards on January 30, 2026: 204,000 restricted stock units (RSUs) and 320,000 derivative awards (stock options). Both grants are reported at $0.00 because they are compensatory awards, not open-market purchases or sales.

Key Details

Transaction date: 2026-01-30; Form 4 filed 2026-02-03 (timely — within the two-business-day filing window).
Grants: 204,000 RSUs (reported acquisition amount $0.00) and 320,000 derivative awards/options (reported acquisition amount $0.00).
Vesting (per footnotes): RSUs vest one-third on each of the first, second and third anniversaries of the grant date, subject to continued service. Options vest over four years: 25% at the first anniversary, then the remainder in equal quarterly installments thereafter, subject to continued service.
Holdings note: footnotes also reference 3,000 shares bought under the company’s ESPP in 2025 (1,500 on June 30, 2025 and 1,500 on Dec 31, 2025). The filing does not state the total shares owned by Burke after these grants.
Nature of transaction: Award/Grant (code A) — no cash paid now; these are compensation awards, not immediate purchases or sales.

Context

These are standard compensation awards under Akebia’s 2023 Stock Incentive Plan meant to align executive pay with long-term performance. The derivative award is an option grant (not an exercise); no shares were sold or exercised at grant. Such grants are common and do not by themselves indicate current buying or selling sentiment.

Form 4

Period: 2026-01-30

SVP, Chief Medical Officer

Transactions

Award
Common Stock
[F1][F2]
2026-01-30+204,000→ 1,016,090 total
Award
Stock Option (Right to buy)
[F3]
2026-01-30+320,000→ 320,000 total
Exercise: $1.41Exp: 2036-01-30→ Common Stock (320,000 underlying)

Footnotes (3)

[F1]The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
[F2]Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2025 and 1,500 shares of the Issuer's common stock purchased on December 31, 2025, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
[F3]The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

Signature

/s/ Carolyn M. Rucci, attorney-in-fact for Steven K. Burke|2026-02-03

1 file